Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose

Objective: This study included patients with inoperable primary or recurrent cervical cancer whose treatment plan called for exclusive radiotherapy. The endopoints of the study were to confirm the feasibility of concurrent radiotherapy and paclitaxel in relation to potential acute toxicity and to evaluate if an increase of complete local control might be obtained with the association of paclitaxel to radiotherapy as a radiosensitizer.

Methods: Twenty patients (13 new cases, stage IIB-III, and 7 with pelvic recurrences) were enrolled and, with exclusion of one recurrence, 19 were evaluable for acute toxicity and response. In new cases, radiotherapy was conventionally administered: 50.4 Gy/28 fractions by external beam (whole pelvis) followed by intracavitary cesium or reduced transcutaneous field. In recurrences, radiotherapy was performed with external beam only through individualized fields. Paclitaxel was administered weekly at the dose of 40 mg/m2 or 60 mg/m2 during the entire course of external radiotherapy.

Results: Complete regression (CR) as defined by clinical and imaging examinations was achieved in eight of the 13 new cases (62%) and in four of the six recurrences (66%), for a total complete response rate equal to 63%. Five patients (3 treated with 40 mg/m2 and 2 with 60 mg/m2) experienced grade 3 small bowel toxicity, one patient treated with 40 mg/m2 grade 3 bladder toxicity and one patient treated with 60 mg/m2 had grade 4 mucositis. Out of 12 CR patients at the end of treatment, ten maintain complete local remission for a median follow-up of 47 months but two have developed distant metastases.

Conclusion: The results confirm that this approach is feasible and suggest the use of paclitaxel as radiosensitizer in locally advanced cervical cancer.

Paclitaxel; Radiosensitizer; Cervical cancer

[1] Choy H., Rodriguez F. F., Koester S., Hilsenbeck S., Von Hoff D. D.: "Investigation of taxol as a potential radiation sensitizer". Cancer, 1993, 71, 3774.

[2] Zaffaroni N.: Personal communication.

[3] Schiff P. B., Gubits R., Kashimawo S.: "Interaction with ionizing radiation". In: "Paclitaxel in Cancer Treatment". McGuire W. P., Rowinsky E. K. (eds.). New York: Marcel Dekker Inc., 1995, 81.

[4] Tishler R. B., Schiff P. B., Geard C. R., Hall E. J.: "Taxol a novel radiation sensitizer". Int. J. Radiat. Oneal. Biol. Phys., 1992, 22, 613.

[5] Tishler R. B., Geard C. R., Hall E. J., Schiff P. B.: "Taxol sensitizes human astrocytoma cells to radiation". Cancer Res., 1992, 52, 3495.

[6] Rodriguez M., Sevin B. U., Perras J., Nguyen H. N., Pham C., Steren A. J. et al.: "Paclitaxel: a radiation sensitizer of human cervical cancer cells". Gynecol. Oneal., 1995, 57, 165.

[7] Geard C. R., Jones J.M.: "Radiation and taxol effects on synchronized human cervical carcinoma cells". Int. J. Radiat. Oneal. Biol. Phys., 1994, 29, 565.

[8] Erlich E., McCall A. R., Potkul R. K., Walter S., Vaughan A.: "Paclitaxel is only a weak radiosensitizer of human cervical carcinoma cell lines". Gynecol. Oneal., 1996, 60, 251.

[9] Rosenthal D. I., Close L. G., Lucci J. A. 3'', Schold S. C., Truelson J., Fathallah-Skaykh H. et al.: "Phase I studies of continuousinfusion paclitaxel given with standard aggressive radiation therapy for locally advanced solid tumors". Semin. Oneal., 1995, 22 (suppl.), 13.

[10] Akerley W., Choy H.: "Concurrent paclitaxel and thoracic radiation for advanced non-small cell lung cancer". Lung Cancer, 1995, 12 (suppl.), SI07.

[11] Choy H., Safran H.: "Preliminary analysis of a phase II study of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer". Semin. Oneal., 1995, 22 (suppl.), 55.

[12] Antonia S. J., Wagner H., Williams C., Alberts M., Hubbell D., Robinson L. et al.: "Concurrent paclitaxel/cisplatin with thoracic radiation in patients with stage IIIA/B non-small cell carcinoma of the lung". Semin. Oneal., 1995, 22 (suppl.), 34.

[13] Greco F. A., Stroup S. L., Hainsworth J. D.: "Paclitaxel by I-hour infusion in combination chemotherapy of stage III non-small cell lung cancer". Semin. Oneal., 1995, 22 (suppl.), 75.

[14] Chen M. D., Paley P. J., Potish R. A., Twiggs L. B.: "Phase I trial of Taxol as a radiation sensitizer with cisplatin in advanced cervical cancer". Gynecol. Oneal., 1997, 67, 131.

[15] Pignata S., Frezza P., Tramontana S., Perrone F., Tambaro R., Casella G. et al.: "Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of the cervix uteri". Annals of Oncology, 2000, 11, 455.

[16] International Federation of Gynecology and Obstetrics: "Staging announcement: FIGO staging of gynecologic cancers: cervical and vulva". Int. J. Gynecol. Cancer., 1995, 5, 319.

[17] International Commission on Radiation Units and Measurements. Prescribing, Recording, and Reporting Photon Beam Therapy, ICRU Report 50, Bethesda, 1993.

[18] WHO Recommendations for grading of acute and subacute toxic effects. In WHO handbook for reporting results of cancer treatment. WHO, Geneva, 1979.

[19] Perez C. A., Breaux S.,M adoc-Jones H., Bedwinek J.M., Camel H. M., Purdy J. A. et al.: "Radiation therapy alone in the treatment of carcinoma of the uterine cervix. I. Analysis of tumor recurrence". Cancer, 1983, 51, 1393.

[20] Jacobs A. J., Faris C., Perez C. A., Kao M. S., Galakatos A., Camel H. M.: "Short-term persistence of carcinoma of the uterine cervix after radiation". An indicator of long-term prognosis". Cancer, 1986, 57, 944.

[21] Thomas G. M.: "Improved treatment for cervical cancer. Concurrent chemotherapy and radiotherapy". N. Engl. J. Med., 1999, 340, 1198.

[22] Thomas G., Dembo A., Fyles A., Gadalla T., Beale F., Bean H. et al.: "Concurrent chemoradiation in advanced cervical cancer". Gynecol. Oncol., 1990, 38, 446.

[23] Nguyen P. D., John B.,M unoz A. K.,Y azigi R., GrahamM ., FrankJin P.: "Mitomycin-C/5-FU and radiation therapy for locally advanced uterine cervical cancer". Gynecol. Oneal., 1991, 43, 220.

[24] Khoury G. G., Bulman A. S., Joslin C. A., Rothwell R. I.: "Concomitant pelvic irradiation, 5-fluorouracil and mitomycin C in the treatment of advanced cervical carcinoma". Br. J. Radiol., 1991, 64, 252.

[25] Thomas G. M., Dembo A. J., Myhr T., Black B., Pringle J. F., Rawlings G.: "Long-term results of concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after surgery". Int. J. Gynecol. Cancer, 1993, 3, 193.

[26] Christie D. R., Bull C. A., Gebski V., Langlands A. 0.: "Concurrent 5-tluorouracil. mitomycin C and irradiation in locally advanced cervix cancer". Radiother. Oncol., 1995, 37, 181.

[27] Ludgate S. M.. Crandon A. J., Hudson C. N:, Walker Q., Langlands A. 0.: "Synchronous 5-tluorouracil, mitomycin-C and radiation therapy in the treatment of locally advanced carcinoma of the cervix". Int. J. Radial. Oneal. Biol. Phys., 1988, 15, 893.

[28] Evans L. S., Kersh C. R., Constable W. C., Taylor P. T.: "Concomitant 5-fluorouracil, mitomycin-C, and radiotherapy for advanced gynecologic malignancies". Int. J. Radial. Oneal. Biol. Phys., 1988, 15,901.

[29] Kersh C. R., Constable W. C.. Spaulding C. A., Hahn S. S., Andersen W. A., Taylor P. T.: "A phase I-II trial of multimodality management of bulky gynecologic malignancy. Combined chemoradiosensitization and radiotherapy". Cancer, 1990, 66, 30.

[30] Drescher C. W., Reid G. C., Terada K., Roberts J. A., Hopkins M P., Perez-Tamayo C. et al.: "Continuous infusion of low-dose 5-tluorouracil and radiation therapy for poor-prognosis in squamous cell carcinoma of the uterine cervix". Gynecol. On col., 1992, 44, 227.

[31] Malfetano J., Keys H., Kredentser D., Cunningham M., Kotlove D., Weiss L.: "Weekly cisplatin and radical therapy for advanced, recurrent, and poor prognosis cervical carcinoma". Cancer, 1993, 71, 3703.

[32] Fields A. L., Anderson P. S.. Goldberg G. L., Wadler S., Beitler J., Sood B. et al.: "Mature results of a phase II trial of concomitant cisplatin/pelvic radiotherapy for locally advanced squamous cell carcinoma of the cervix". Gynecol. Oncol., 1996, 61, 416.

[33] Pearcy R. G., Stuart G. C., MacLean G. D., Nation J. G., Arthur K., Lukka H. et al.: "Phase II study to evaluate the toxicity and efficacy of concurrent cisplatin and radiation therapy in the treatment of patients with locally advanced squamous cell carcinoma of the cervix'·. Gynecol. Oncol., 1995, 58, 34.

[34] Lin J. C.. Ho E. S., Jan J. S., Yang C. H.. Liu F. S.: "High complete response rate of concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the uterine cervix" Gynecol. Oneal., 1996, 61, 101.

[35] Chang H. C., Lai C. H.. Chen M. S., Chao A. S., Chen L. H.. Soong Y. K.: "Preliminary results of concurrent radiotherapy and chemotherapy with cisplatinum, vincristine, and bleomycin in bulky, advanced cervical carcinoma: a pilot study". Gynecol Oncol.. 1992, 44, 182

[36] Morris M., Eifel P. J.. Lu J., Grigsby P. W., Levenback C., Stevens R. E. et al.: "Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer". N. Engl. J. Med., 1999, 340, 1137.

[37] Rose P. G.. Bundy B. N., Watkins E. 8., Thigpen T. J., Deppe G., Maiman M.A. et al.: "Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer". N. Engl J. Med., 1999, 340, 1144.

[38] Whitney C. W., Sause W.. Bundy B. N.. Malfetano J. H., Hannigan E. V.. Fowler W. C. Jr. et al.: "Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-TVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Group study". J. Clin. Oneal., 1999, 17, 1339.